ClinicalTrials.gg
CompletedNCT01117766Updated Apr 23, 2019Results posted

Study To Assess The Reproducibility And Sensitivity Of Quantitative Sensory Testing In Patients With Neuropathic Pain

An interventional study of Pregabalin and Placebo in Neuropathic Pain, sponsored by Pfizer. Completed at 5 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-23.

Sponsored by Pfizer · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing pregabalin in Neuralgia — 4 open to participants now, 4 under way, 1 of them phase 3. Pregabalin · Neuralgia.

Enrollment
44th of 50
31 · median 109
Started
2006
with 5 others
No phase
10 of 50
2 open now
Registered
21st of 50
by date
Lead sponsor
3 of 50
Pfizer

Among the 50 studies testing pregabalin in Neuralgia, this one is the 44th largest by enrollment, is one of 6 that started in 2006, is one of 10 with no phase, and was the 21st registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

4 of the 50 studies testing pregabalin in Neuralgia are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing pregabalin in Neuralgia, or all of them as a file.
02

Study summary

Conventional pain efficacy measures such as Visual Analogue Scores (VAS) are often unable to detect treatment efficacy in small-scale clinical trials. Combining conventional pain efficacy measures with quantitative sensory testing (QST) may provide more sensitive and informative outcome measures in clinical trials.

Read the detailed description

Methodology to assess reproducibility and sensitivity of quantitative sensory testing

03

Conditions studied

  • Neuropathic Pain

Browse trials for

Keywords

  • Methodology
  • Quantitative Sensory Testing
  • Neuropathies Pain
  • Pregabalin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neuropathic pain of peripheral origin demonstrating spontaneous ongoing pain and dynamic mechanical allodynia to brush stimuli.
  • A present pain intensity score of 4 or more (out of 10) for spontaneous ongoing pain and brush-evoked allodynia at the skin area at screen.
  • Stable analgesic medication (excluding pregabalin) for a minimum of 1 month prior to the start of study.

Exclusion criteria

Exclusion Criteria:

  • Patients who have undergone neurolytic or neurosurgical therapy.
  • Patients who have trigeminal neuralgia, central pain (due to cerebrovascular lesions, multiple sclerosis and traumatic spinal cord injuries), complex regional pain syndrome (Type I and II), and phantom limb pain.
  • Patients who have previously been treated with pregabalin.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Active comparator
    Active drug

    Drug: Pregabalin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients

  • DrugPlacebo

    BID dosing for 28 days

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Dynamic Allodynia Intensity at Visits 3 and 6 and Visits 4 and 7

    Five strokes applied with a standardized brush (somedic) across the painful site, 6cm long and at a control site to allow the participants to appreciate any difference. A painful and clearly dysaesthetic (unpleasant) sensation was considered as representing brush allodynia (whereas a "strange" or "tickly" sensation provoked by the brush was not). After each brush stimuli participants were asked to give a pain rating using 11-point numerical rating scale (NRS) where 0=no pain and 10=worst pain imaginable. The average of 5 brush strokes was calculated to obtain the mean score.

    Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period

  2. Mean Change From Baseline in Dynamic Allodynia Area at Visits 3 and 6 and Visits 4 and 7

    Dynamic area brush in cm\^2: calculated from 8 measured distances by calculating the area of an octagon. The angle between each pair of lines was 45 degrees at point c. The area of the octagon was found by totaling the areas of the 8 triangles. Octagon with 8 radial lengths from center to the outside. Area = Σ ( ½ length \* perpendicular height); Σ ( ½ ri \* sin(45) r(i+1) ) = Σ ( (ri \* r(i+1) )/2√2)). (where ri, i=1 to 8, were the eight radial lengths)

    Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period

  3. Mean Change From Baseline in Mechanical Pain Sensitivity (Von Frey) at Visits 3 and 6 and Visits 4 and 7

    Sensitivity to mechanical pain stimuli was tested using calibrated Von Frey monofilaments. To obtain a stimulus-response-function, seven different Von Frey monofilaments (size 8 to 512 mN, force increased by a factor of two from filament to filament) applied three times each; each stimulus was participant-rated using 11-point NRS where 0=no pain and 10=worst pain imaginable. If a score of 8 or more was reported for a given intensity no stronger stimuli was applied. Von Frey stimulus was applied to the skin for 1 to 2 seconds. The average of 3 ratings was calculated for the mean score.

    Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period

  4. Mean Change From Baseline in Punctate Allodynia Area (Von Frey) at Visits 3 and 6 and Visits 4 and 7

    Punctate allodynia area in cm\^2: calculated from 8 measured distances by calculating the area of an octagon. The angle between each pair of lines was 45 degrees at point c. The area of the octagon was found by totaling the areas of the 8 triangles. Octagon with 8 radial lengths from center to the outside. Area = Σ ( ½ length \* perpendicular height); Σ ( ½ ri \* sin(45) r(i+1) ) = Σ ( (ri \* r(i+1) )/2√2)). (where ri, i=1 to 8, were the eight radial lengths)

    Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period

  5. Mean Change From Baseline in Cold Pain Sensitivity at Visits 3 and 6 and Visits 4 and 7

    Duration of thermal stimuli was 2 seconds and an intensity that is increased in steps of 5 degrees celsius for cold stimuli (between 5 and 20 degrees celsius). Thermal pain sensitivity was participant-rated using 11-point NRS where 0=no pain and 10=worst pain imaginable. The average of 2 ratings was calculated to get the mean score.

    Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period

  6. Mean Change From Baseline in Heat Pain Sensitivity at Visits 3 and 6 and Visits 4 and 7

    Duration of thermal stimuli was 2 seconds and an intensity that is increased in steps of 4 degrees celsius for heat stimuli (between 40 and 50 degrees celsius). Thermal pain sensitivity was participant-rated using 11-point NRS where 0=no pain and 10=worst pain imaginable. The average of 2 ratings was calculated to get the mean score.

    Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period

Secondary outcomes

  1. Mean Change From Baseline in Weekly Pain Score From the Daily Diary at Visits 3 and 6 and Visits 4 and 7

    Daily pain diary: participant-rated pain during the past 24 hours rated on an 11 point NRS scale where 0=no pain and 10=worst possible pain. For a given week, the pain response was the average of the 7 daily entries for that week, or average of the available data for that week if fewer than 7 entries were recorded (\>=1 daily pain score for any given week required). The endpoint for each week consisted of the change from baseline in average pain score (follow-up value minus baseline).

    Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period

  2. Mean Change From Baseline in Patient's Global Impression of Change (PGIC) at Visits 3 and 6 and Visits 4 and 7

    PGIC: participant-rated assessment measuring change in participant's overall status on a 7-point scale from 1=very much improved to 7=very much worse.

    Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period

  3. Mean Change From Baseline in Test-Day Global Pain Intensity at Visits 3 and 6 and Visits 4 and 7

    Global pain: participant-rated pain using the test-day global pain scale, consisting of an 11-point NRS where 0 = no pain and 10 = worst possible pain. Participants described intensity of pain in response to "How intense is your pain today?"

    Time frame: Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period

  4. Mean Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) Total Score at Visits 4 and 7

    NPSI: 10-item self-administered questionnaire assessing 5 dimensions of pain (burning superficial spontaneous pain, pressing deep spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia). Each item consists of a question about the specific qualities of pain and an 11-point numerical scale range: 0 (absence of pain) to 10 (maximum intensity imaginable), and 2 temporal items related to spontaneous and paroxysmal pain. Maximum total score possible = 100.

    Time frame: Week 4 (Visits 4 and 7) of each period

07

Results

Posted Sep 27, 2010

Participant flow

First Intervention
Participant flow — First Intervention
MilestonePregabalin Then PlaceboPlacebo Then Pregabalin
Started1417
Received treatment1417
Completed1316
Not completed11
Withdrew: Adverse event01
Withdrew: Protocol violation10
Washout Period
Participant flow — Washout Period
MilestonePregabalin Then PlaceboPlacebo Then Pregabalin
Started1316
Completed1314
Not completed02
Withdrew: Protocol violation02
Second Intervention
Participant flow — Second Intervention
MilestonePregabalin Then PlaceboPlacebo Then Pregabalin
Started1314
Completed119
Not completed25
Withdrew: Lost to follow-up10
Withdrew: Other12
Withdrew: Adverse event02
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryMean Change From Baseline in Dynamic Allodynia Intensity at Visits 3 and 6 and Visits 4 and 7

Five strokes applied with a standardized brush (somedic) across the painful site, 6cm long and at a control site to allow the participants to appreciate any difference. A painful and clearly dysaesthetic (unpleasant) sensation was considered as representing brush allodynia (whereas a "strange" or "tickly" sensation provoked by the brush was not). After each brush stimuli participants were asked to give a pain rating using 11-point numerical rating scale (NRS) where 0=no pain and 10=worst pain imaginable. The average of 5 brush strokes was calculated to obtain the mean score.

Time frame:
Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Reported as:
Mean · scores on a scale
Mean Change From Baseline in Dynamic Allodynia Intensity at Visits 3 and 6 and Visits 4 and 7
scores on a scalePregabalinPlacebo
Week 3 (Visits 3 and 6) (n=15,16)-1.09 ± 1.735-1.16 ± 1.730
Week 4 (Visits 4 and 7) (n=18,21)-1.31 ± 1.924-0.67 ± 1.984
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.7319 · Mean difference (net): -0.19 · 95% CI -1.29 to 0.92
  • Pregabalin vs Placebo · ANCOVA · p = 0.3404 · Mean difference (net): -0.52 · 95% CI -1.61 to 0.57
PrimaryMean Change From Baseline in Dynamic Allodynia Area at Visits 3 and 6 and Visits 4 and 7

Dynamic area brush in cm\^2: calculated from 8 measured distances by calculating the area of an octagon. The angle between each pair of lines was 45 degrees at point c. The area of the octagon was found by totaling the areas of the 8 triangles. Octagon with 8 radial lengths from center to the outside. Area = Σ ( ½ length \* perpendicular height); Σ ( ½ ri \* sin(45) r(i+1) ) = Σ ( (ri \* r(i+1) )/2√2)). (where ri, i=1 to 8, were the eight radial lengths)

Time frame:
Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Reported as:
Mean · cm2
Mean Change From Baseline in Dynamic Allodynia Area at Visits 3 and 6 and Visits 4 and 7
cm2PregabalinPlacebo
Week 3 (Visits 3 and 6) (n=16,17)-53.441 ± 114.7084-49.180 ± 94.3329
Week 4 (Visits 4 and 7) (n=17,20)-49.808 ± 100.2094-18.921 ± 104.3942
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.6539 · Mean difference (net): -12.32 · 95% CI -70.20 to 45.56
  • Pregabalin vs Placebo · ANCOVA · p = 0.3678 · Mean difference (net): -23.91 · 95% CI -78.54 to 30.72
PrimaryMean Change From Baseline in Mechanical Pain Sensitivity (Von Frey) at Visits 3 and 6 and Visits 4 and 7

Sensitivity to mechanical pain stimuli was tested using calibrated Von Frey monofilaments. To obtain a stimulus-response-function, seven different Von Frey monofilaments (size 8 to 512 mN, force increased by a factor of two from filament to filament) applied three times each; each stimulus was participant-rated using 11-point NRS where 0=no pain and 10=worst pain imaginable. If a score of 8 or more was reported for a given intensity no stronger stimuli was applied. Von Frey stimulus was applied to the skin for 1 to 2 seconds. The average of 3 ratings was calculated for the mean score.

Time frame:
Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Reported as:
Mean · scores on a scale
Mean Change From Baseline in Mechanical Pain Sensitivity (Von Frey) at Visits 3 and 6 and Visits 4 and 7
scores on a scalePregabalinPlacebo
Week 3 (Visits 3 and 6) (Size 8, n=15,16)-0.133 ± 1.74940.417 ± 2.6063
Week 3 (Visits 3 and 6) (Size 16, n=15,16)-1.356 ± 2.48000.208 ± 2.6412
Week 3 (Visits 3 and 6) (Size 32, n=15,16)-0.200 ± 1.8551-0.188 ± 2.1636
Week 3 (Visits 3 and 6) (Size 64, n=15,16)-1.128 ± 2.03040.561 ± 2.9543
Week 3 (Visits 3 and 6) (Size 128, n=15,16)-1.267 ± 1.6868-0.097 ± 1.3385
Week 3 (Visits 3 and 6) (Size 256, n=15,16)-0.773 ± 2.2420-0.171 ± 1.4133
Week 3 (Visits 3 and 6) (Size 512, n=15,16)-1.533 ± 1.7873-0.480 ± 1.1183
Week 4 (Visits 4 and 7) (Size 8, n=18,21)-0.370 ± 1.2674-0.429 ± 1.7132
Week 4 (Visits 4 and 7) (Size 16, n=18,21)-0.611 ± 1.2693-0.889 ± 2.2616
Week 4 (Visits 4 and 7) (Size 32, n=18,21)-0.333 ± 1.4597-0.825 ± 2.1386
Week 4 (Visits 4 and 7) (Size 64, n=18,21)-1.116 ± 1.6152-0.462 ± 3.1381
Week 4 (Visits 4 and 7) (Size 128, n=18,21)-1.315 ± 1.9322-0.841 ± 2.2843
Week 4 (Visits 4 and 7) (Size 256, n=18,21)-1.322 ± 1.8729-0.751 ± 2.5072
Week 4 (Visits 4 and 7) (Size 512, n=18,21)-1.836 ± 1.7249-0.420 ± 2.0238
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0071 · Mean difference (net): -1.09 · 95% CI -1.84 to -0.35Statistical analysis was based on the average pain score across all levels of stimuli.
  • Pregabalin vs Placebo · ANCOVA · p = 0.1294 · Mean difference (net): -0.59 · 95% CI -1.36 to 0.19Statistical analysis was based on the average pain score across all levels of stimuli.
PrimaryMean Change From Baseline in Punctate Allodynia Area (Von Frey) at Visits 3 and 6 and Visits 4 and 7

Punctate allodynia area in cm\^2: calculated from 8 measured distances by calculating the area of an octagon. The angle between each pair of lines was 45 degrees at point c. The area of the octagon was found by totaling the areas of the 8 triangles. Octagon with 8 radial lengths from center to the outside. Area = Σ ( ½ length \* perpendicular height); Σ ( ½ ri \* sin(45) r(i+1) ) = Σ ( (ri \* r(i+1) )/2√2)). (where ri, i=1 to 8, were the eight radial lengths)

Time frame:
Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Reported as:
Mean · cm2
Mean Change From Baseline in Punctate Allodynia Area (Von Frey) at Visits 3 and 6 and Visits 4 and 7
cm2PregabalinPlacebo
Week 3 (Visits 3 and 6) (n=16,17)-75.571 ± 148.8301-3.232 ± 125.8041
Week 4 (Visits 4 and 7) (n=17,20)-75.834 ± 133.9530-4.130 ± 129.8261
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0300 · Mean difference (net): -61.54 · 95% CI -116.12 to -6.96
  • Pregabalin vs Placebo · ANCOVA · p = 0.0844 · Mean difference (net): -49.06 · 95% CI -105.67 to 7.55
PrimaryMean Change From Baseline in Cold Pain Sensitivity at Visits 3 and 6 and Visits 4 and 7

Duration of thermal stimuli was 2 seconds and an intensity that is increased in steps of 5 degrees celsius for cold stimuli (between 5 and 20 degrees celsius). Thermal pain sensitivity was participant-rated using 11-point NRS where 0=no pain and 10=worst pain imaginable. The average of 2 ratings was calculated to get the mean score.

Time frame:
Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Reported as:
Mean · scores on a scale
Mean Change From Baseline in Cold Pain Sensitivity at Visits 3 and 6 and Visits 4 and 7
scores on a scalePregabalinPlacebo
Week 3 (Visits 3 and 6) (5 degrees, n=15,16)-0.821 ± 1.2039-1.402 ± 3.0295
Week 3 (Visits 3 and 6) (10 degrees, n=15,16)-0.333 ± 1.3318-1.313 ± 2.0402
Week 3 (Visits 3 and 6) (15 degrees, n=15,16)-0.567 ± 2.34420.125 ± 1.3478
Week 3 (Visits 3 and 6) (20 degrees, n=15,16)-0.500 ± 1.93650.031 ± 1.4314
Week 4 (Visits 4 and 7) (5 degrees, n=18,21)-0.726 ± 1.3375-0.703 ± 2.4746
Week 4 (Visits 4 and 7) (10 degrees, n=18,21)-0.278 ± 1.3086-0.810 ± 1.6239
Week 4 (Visits 4 and 7) (15 degrees, n=18,21)-0.583 ± 1.26320.095 ± 1.5622
Week 4 (Visits 4 and 7) (20 degrees, n=18,21)-0.111 ± 1.4507-0.333 ± 0.7130
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.7506 · Mean difference (net): 0.15 · 95% CI -0.83 to 1.14Statistical analysis was based on the average pain score across all levels of stimuli.
  • Pregabalin vs Placebo · ANCOVA · p = 0.9673 · Mean difference (net): 0.01 · 95% CI -0.61 to 0.64Statistical analysis was based on the average pain score across all levels of stimuli.
PrimaryMean Change From Baseline in Heat Pain Sensitivity at Visits 3 and 6 and Visits 4 and 7

Duration of thermal stimuli was 2 seconds and an intensity that is increased in steps of 4 degrees celsius for heat stimuli (between 40 and 50 degrees celsius). Thermal pain sensitivity was participant-rated using 11-point NRS where 0=no pain and 10=worst pain imaginable. The average of 2 ratings was calculated to get the mean score.

Time frame:
Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Reported as:
Mean · scores on a scale
Mean Change From Baseline in Heat Pain Sensitivity at Visits 3 and 6 and Visits 4 and 7
scores on a scalePregabalinPlacebo
Week 3 (Visits 3 and 6) (40 degrees, n=15,16)-1.100 ± 2.2216-0.625 ± 2.3130
Week 3 (Visits 3 and 6) (44 degrees, n=15,16)0.400 ± 3.4959-0.938 ± 2.8395
Week 3 (Visits 3 and 6) (47 degrees, n=15,16)-0.908 ± 2.5249-0.578 ± 3.3112
Week 3 (Visits 3 and 6) (50 degrees, n=15,16)-1.385 ± 2.8981-0.865 ± 2.1050
Week 4 (Visits 4 and 7) (40 degrees, n=18,21)-0.639 ± 2.5771-0.143 ± 0.9506
Week 4 (Visits 4 and 7) (44 degrees, n=18,21)-0.444 ± 4.1084-0.495 ± 2.9959
Week 4 (Visits 4 and 7) (47 degrees, n=18,21)-0.337 ± 3.0065-0.083 ± 2.7679
Week 4 (Visits 4 and 7) (50 degrees, n=18,21)-0.566 ± 2.2423-0.387 ± 2.6689
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.5502 · Mean difference (net): 0.39 · 95% CI -0.99 to 1.78Statistical analysis was based on the average pain score across all levels of stimuli.
  • Pregabalin vs Placebo · ANCOVA · p = 0.8536 · Mean difference (net): -0.09 · 95% CI -1.15 to 0.96Statistical analysis was based on the average pain score across all levels of stimuli.
SecondaryMean Change From Baseline in Weekly Pain Score From the Daily Diary at Visits 3 and 6 and Visits 4 and 7

Daily pain diary: participant-rated pain during the past 24 hours rated on an 11 point NRS scale where 0=no pain and 10=worst possible pain. For a given week, the pain response was the average of the 7 daily entries for that week, or average of the available data for that week if fewer than 7 entries were recorded (\>=1 daily pain score for any given week required). The endpoint for each week consisted of the change from baseline in average pain score (follow-up value minus baseline).

Time frame:
Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Reported as:
Mean · scores on a scale
Mean Change From Baseline in Weekly Pain Score From the Daily Diary at Visits 3 and 6 and Visits 4 and 7
scores on a scalePregabalinPlacebo
Week 3 (Visits 3 and 6) (n=19,18)-1.456 ± 1.8287-0.484 ± 2.0721
Week 4 (Visits 4 and 7) (n=18,18)-1.397 ± 1.4823-0.769 ± 1.4778
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.0132 · Mean difference (net): -1.54 · 95% CI -2.73 to -0.34In statistical analyses, scores were further grouped to 1-3 'improved', 4 'no change' and 5-7 'worsened'.
  • Pregabalin vs Placebo · ANCOVA · p = 0.0403 · Mean difference (net): -1.00 · 95% CI -1.95 to -0.05In statistical analyses, scores were further grouped to 1-3 'improved', 4 'no change' and 5-7 'worsened'.
SecondaryMean Change From Baseline in Patient's Global Impression of Change (PGIC) at Visits 3 and 6 and Visits 4 and 7

PGIC: participant-rated assessment measuring change in participant's overall status on a 7-point scale from 1=very much improved to 7=very much worse.

Time frame:
Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Reported as:
Mean · scores on a scale
Mean Change From Baseline in Patient's Global Impression of Change (PGIC) at Visits 3 and 6 and Visits 4 and 7
scores on a scalePregabalinPlacebo
Week 3 (Visits 3 and 6) (n=15,16)3.3 ± 1.873.4 ± 1.15
Week 4 (Visits 4 and 7) (n=18,21)2.4 ± 1.203.8 ± 1.63
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.6631 · Mean difference (net): -0.19 · 95% CI -1.12 to 0.74
  • Pregabalin vs Placebo · ANCOVA · p = 0.0022 · Mean difference (net): -1.54 · 95% CI -2.48 to -0.59
SecondaryMean Change From Baseline in Test-Day Global Pain Intensity at Visits 3 and 6 and Visits 4 and 7

Global pain: participant-rated pain using the test-day global pain scale, consisting of an 11-point NRS where 0 = no pain and 10 = worst possible pain. Participants described intensity of pain in response to "How intense is your pain today?"

Time frame:
Week 3 (Visits 3 and 6) and Week 4 (Visits 4 and 7) of each period
Reported as:
Mean · scores on a scale
Mean Change From Baseline in Test-Day Global Pain Intensity at Visits 3 and 6 and Visits 4 and 7
scores on a scalePregabalinPlacebo
Week 3 (Visits 3 and 6) (n=7,10)-1.5 ± 2.39-0.4 ± 2.66
Week 4 (Visits 4 and 7) (n=11,11)-1.6 ± 1.950.0 ± 2.94
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.1753 · Mean difference (net): -1.04 · 95% CI -2.60 to 0.53
  • Pregabalin vs Placebo · ANCOVA · p = 0.0198 · Mean difference (net): -1.51 · 95% CI -2.75 to -0.27
SecondaryMean Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) Total Score at Visits 4 and 7

NPSI: 10-item self-administered questionnaire assessing 5 dimensions of pain (burning superficial spontaneous pain, pressing deep spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia). Each item consists of a question about the specific qualities of pain and an 11-point numerical scale range: 0 (absence of pain) to 10 (maximum intensity imaginable), and 2 temporal items related to spontaneous and paroxysmal pain. Maximum total score possible = 100.

Time frame:
Week 4 (Visits 4 and 7) of each period
Reported as:
Mean · scores on a scale
Mean Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) Total Score at Visits 4 and 7
scores on a scalePregabalinPlacebo
Mean Change From Baseline in Neuropathic Pain Symptom Inventory (NPSI) Total Score at Visits 4 and 7-10.67 ± 21.404-7.72 ± 19.384
Statistical analysis
  • Pregabalin vs Placebo · ANCOVA · p = 0.4999 · Mean difference (net): -4.29 · 95% CI -17.13 to 8.54

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—1/28 (3.6%)20/28 (71.4%)
Placebo—1/30 (3.3%)15/30 (50%)
Most frequent serious events
Most frequent serious events
EventPregabalinPlacebo
Menopause and related conditionsReproductive system and breast disorders1/281/30
Postmenopausal haemorrhageReproductive system and breast disorders1/281/30
Most frequent other events
Showing 10 of 54
Most frequent other events
EventPregabalinPlacebo
SomnolenceNervous system disorders7/281/30
FatigueGeneral disorders6/284/30
Dry mouthGastrointestinal disorders4/281/30
DizzinessNervous system disorders4/282/30
VertigoEar and labyrinth disorders3/281/30
Disturbance in attentionNervous system disorders3/281/30
NauseaGastrointestinal disorders1/283/30
Vision blurredEye disorders2/280/30
DiarrhoeaGastrointestinal disorders2/281/30
Tongue coatedGastrointestinal disorders2/280/30

Baseline characteristics

Age, Customized
Age, Customized(participants)All Participants
18 to 44 years9
45 to 64 years12
>=65 years10
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female18
Male13
08

Study locations

5 sites
  • Pfizer Investigational Site
    Vienna, A-1090, Austria
  • Pfizer Investigational Site
    Bruxelles, 1070, Belgium
  • Pfizer Investigational Site
    Boulogne Billancourt, 92100, France
  • Pfizer Investigational Site
    Liverpool, L9 7AL, United Kingdom
  • Pfizer Investigational Site
    London, SW10 9NH, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2010
First posted
May 5, 2010
Start
Dec 2006
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Sep 27, 2010
Last update
Apr 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01117766
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 5, 2010
Start date
Dec 2006
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Sep 27, 2010
Last update
Apr 23, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion